Omeros Corporation OMER

pangx623 Pro Updated 

Opportunity for a massive short squeeze. Need volume to confirm a short squeeze is taking place. Stop below today's low. Short float >20%. You don't need to know what's going to happen next to make money ~Mark Douglas Lose like a pro and keep trading, or lose like a novice and quit ~Mark Ritchie

CryptoFundManager Premium

In 2021 Omeros Corporation (OMER) delivered great results, net income was $194.2 million or $3.12 per share VS a net loss of $138.1 million or $2.41 net loss per share in 2020. On 1/18/2022 Cantor Fitzgerald Lower Price Target for OMER from $34.00 to $20.00. I think a reversal to the $8.50 resistance is possible. Looking forward to read your opinion about it.

samitrading Updated 

Since short squeezes are the fashion now, this is a mini series for them #7

TradingMula Pro+ Updated 

Swing long target $18.50

savepiginvest Pro

Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA -- FDA sets PDUFA date of July 17, 2021 --

oozyi

omer

oozyi

omer

Shahkulu Premium Updated 

$OMER - Renko (90 ATR, 90 min) we use stoch/mfi/rsi together with default settings. this is a very choppy chart to analyze if you chart it normally. renko allows us to filter that choppiness. Stoch oversold, MFI on trigger zone, RSI moving to oversold zone. we must wait for the price to reverse to neckline before we make entry ( > $12.50 ) also this may be a...

STOCKRETURN Premium

Looks like I found support

LeLaf Premium

Higher price rejection after gap up May try to fill it in the next few days, If confirmed PT1 = 19,61 PT2 = 14,48 for gap fill

AlenCiken

Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome -- All six patients, requiring mechanical ventilation prior to treatment, recovered, survived and were discharged from the hospital -- Narsoplimab treatment was associated with rapid and sustained improvement across all...

Bullishcharts Premium

Major downtrends broken after earnings beat. Possible entry level above resistance $15.05 Target price $17.17 Stop loss $14.30 Company profile Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications...

honorbear Updated 

triple bottom. adx going up... next stop in 14.20 added to trading postion. 4k.

KAS109 Premium Updated 

Watching for a break above $14.75. nice base consolidation here. Former runner. Ascending wedge pattern. 10, 20 and 50 EMA forming a nice floor for a stop loss. See if it holds $14 or not. No position yet. Risk: biotechs normally I avoid, but this has a nice pattern. Also on guard for any overall market weakness which will probably negate this as a potential...

PlayerXYZ Pro

Omer long nice triangle setup Looking to get in before move up :)

PlayerXYZ Pro

Price Action for Omer Watching for a liquidity grab and volume increase to complete a sloppy inverse HS on Daily charts

PlayerXYZ Pro

Watching volume

joseramonperezq Updated 

good move above prior horizontal resistance, expecting a retest of the new support to go long with a better risk reward ratio.